EA201892532A1 - Pyrimidine-2-Ilamino-1H-Pyrazoles as an LRRK2 inhibitor for use in the treatment of neurodegenerative diseases - Google Patents

Pyrimidine-2-Ilamino-1H-Pyrazoles as an LRRK2 inhibitor for use in the treatment of neurodegenerative diseases

Info

Publication number
EA201892532A1
EA201892532A1 EA201892532A EA201892532A EA201892532A1 EA 201892532 A1 EA201892532 A1 EA 201892532A1 EA 201892532 A EA201892532 A EA 201892532A EA 201892532 A EA201892532 A EA 201892532A EA 201892532 A1 EA201892532 A1 EA 201892532A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ilamino
pyrazoles
pyrimidine
treatment
neurodegenerative diseases
Prior art date
Application number
EA201892532A
Other languages
Russian (ru)
Inventor
Энтони А. Эстрада
Цзяньвэнь А. Фэн
Джозеф П. Лиссикатос
Закари К. Суини
Хавьер Де Висенте Фидальго
Original Assignee
Денали Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Денали Терапьютикс Инк. filed Critical Денали Терапьютикс Инк.
Priority claimed from PCT/US2017/037782 external-priority patent/WO2017218843A1/en
Publication of EA201892532A1 publication Critical patent/EA201892532A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение в целом относится к ингибиторам LRRK2 или их фармацевтически приемлемой соли, дейтерированному аналогу, пролекарству, таутомеру, стереоизомеру или смеси их стереоизомеров и способам их получения и применения.The present invention relates generally to inhibitors of LRRK2 or a pharmaceutically acceptable salt thereof, a deuterated analog, prodrug, tautomer, stereoisomer or mixtures of their stereoisomers and methods for their preparation and use.

EA201892532A 2017-05-24 2017-06-15 Pyrimidine-2-Ilamino-1H-Pyrazoles as an LRRK2 inhibitor for use in the treatment of neurodegenerative diseases EA201892532A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762510711P 2017-05-24 2017-05-24
PCT/US2017/037782 WO2017218843A1 (en) 2016-06-16 2017-06-15 Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
EA201892532A1 true EA201892532A1 (en) 2019-05-31

Family

ID=66644940

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892532A EA201892532A1 (en) 2017-05-24 2017-06-15 Pyrimidine-2-Ilamino-1H-Pyrazoles as an LRRK2 inhibitor for use in the treatment of neurodegenerative diseases

Country Status (1)

Country Link
EA (1) EA201892532A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819405A (en) * 2022-12-20 2023-03-21 沪渝人工智能研究院 Pyrimidinylaminopyrazole derivatives and their use as leucine-rich repeat kinase 2 inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819405A (en) * 2022-12-20 2023-03-21 沪渝人工智能研究院 Pyrimidinylaminopyrazole derivatives and their use as leucine-rich repeat kinase 2 inhibitors

Similar Documents

Publication Publication Date Title
CY1124789T1 (en) PYRIMIDIN-2-YLAMINO-1H-PYRAZOLE AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATE DISORDERS
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
SA518400547B1 (en) Pyrazolopyrimidine Derivatives as Kinase Inhibitor
EA201890318A1 (en) COMPOUNDS OF PYRAZOLO-SUBSTITUTED [1,5-a] PYRIDINE AS RET KINASE INHIBITORS
EA201891229A1 (en) EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS
EA201791576A1 (en) JAK INHIBITOR
EA202090530A1 (en) 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS
EA201692480A1 (en) PHARMACEUTICAL COMPOSITION
EA201791289A1 (en) INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS
EA201692470A1 (en) PHARMACEUTICAL COMBINATIONS
TW201613577A (en) Pharmaceutical combinations
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EA201892532A1 (en) Pyrimidine-2-Ilamino-1H-Pyrazoles as an LRRK2 inhibitor for use in the treatment of neurodegenerative diseases
EA201790020A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
MY195679A (en) Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders
EA201792265A1 (en) METHODS OF TREATING CARDIOVASCULAR DISEASES
EA202091668A3 (en) HUMAN PLASMA CALLICREIN INHIBITORS